Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 2/20 | 0.63 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.63 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.63 |
| ▸ | IL23R | Q5VWK5 | 3/20 | 0.57 |
| ▸ | KISS1R | Q969F8 | 4/20 | 0.56 |
| ▸ | NPY1R | P25929 | 1/20 | 0.55 |
| ▸ | NPY2R | P49146 | 1/20 | 0.55 |
| ▸ | NPY4R | P50391 | 1/20 | 0.55 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.54 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.53 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.53 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29854419 | 0.89 | CRHR1 (0.64) | IL23RCRHR1CRHR2 | |
| SCHEMBL29582948 | 0.86 | CRHR1 (0.68) | CRHR1CRHR2 | |
| SCHEMBL29732401 | 0.85 | TFPI (0.62) | NPBWR1CRHR1CRHR2 | |
| SCHEMBL29468905 | 0.84 | CRHR1 (0.57) | CRHR1CRHR2 | |
| SCHEMBL30589713 | 0.83 | CRHR1 (0.59) | IL23RKISS1RCRHR1CRHR2 | |
| SCHEMBL31332318 | 0.83 | QRFPR (0.57) | OPRK1OPRM1OPRD1NPBWR1 | |
| SCHEMBL31332222 | 0.83 | OPRK1 (0.71) | OPRK1OPRM1OPRD1KISS1RNPY1R | |
| SCHEMBL11309694 | 0.83 | OPRM1 (0.52) | OPRK1OPRM1OPRD1IL23R | |
| SCHEMBL11309707 | 0.83 | OPRM1 (0.52) | OPRK1OPRM1OPRD1IL23R | |
| SCHEMBL29517084 | 0.82 | OPRK1 (0.59) | OPRK1OPRD1IL23RNPBWR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230145599-A1 | Microneedle Array Delivery of Adenovirus Vectored Vaccines With and Without Adjuvants | UNIV OF PITTSBURGH OF THE COMMONWELTH SYSTEM OF HIGHER EDUCATION (US) | 2023-05-11 | — | — | US | claimed |
| EP-4132466-A1 | MICRONEEDLE ARRAY DELIVERY OF ADENOVIRUS VECTORED VACCINES WITH AND WITHOUT ADJUVANTS | University of Pittsburgh - of the Commonwealth System of Higher Education (US) | 2023-02-15 | — | — | EP | claimed |
| EP-4114462-A1 | 2019-NCOV SUBUNIT VACCINE AND MICRONEEDLE ARRAY DELIVERY SYSTEM | University of Pittsburgh - of the Commonwealth System of Higher Education (US) | 2023-01-11 | — | — | EP | claimed |
| WO-2022038131-A1 | METHOD FOR THE PREDICTION OF PROGRESSION OR PROGNOSIS OF THE RESPONSE OF A SUBJECT SUFFERING FROM ACUTE ORGAN DAMAGE | Plus Vitech, S.L. (ES) | 2022-02-24 | — | — | WO | claimed |
| US-20260049331-A1 | Sense-and-Response of Proteins, Peptides, and Small Molecules Using Ligand-Induced Dimerization Activating RNA Editing (LIDAR) | UNIV LELAND STANFORD JUNIOR (US) | 2026-02-19 | — | — | US | disclosed |
| EP-4674959-A1 | NICKING ENZYME, DNA EDITING SYSTEM, TARGET DNA EDITING METHOD, AND METHOD FOR PRODUCING CELL IN WHICH TARGET DNA IS EDITED | Sumitomo Chemical Company, Limited (JP) | 2026-01-07 | — | — | EP | disclosed |
| US-20250270330-A1 | TREATMENT OF HEADACHE DISORDERS WITH NK3 MODULATORS | KALLYOPE, INC. | 2025-08-28 | — | — | US | disclosed |
| US-20250223580-A1 | PROGRAMMABLE NUCLEASE-PEPTIDASE COMPOSITIONS | THE BROAD INSTITUTE, INC. | 2025-07-10 | — | — | US | disclosed |
| WO-2025137264-A1 | SMALL MOLECULE SURROGATE FOR A NEUTRALIZATION EPITOPE ON THE ZIKA VIRUS ENVELOPE PROTEIN | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2025-06-05 | — | — | US | disclosed |
| CN-114867819-B | Carbon quantum dot and use thereof | 北京碳纳医疗科技有限公司 | 2025-03-28 | — | — | CN | disclosed |
| EP-3100729-B1 | USE OF NON-PEPTIDE NK1 ANTAGONISTS IN A PREDETERMINED DOSE FOR THE TREATMENT OF CANCER | SERVICIO ANDALUZ DE SALUD (ES) | 2025-03-19 | — | — | EP | disclosed |
| WO-2022170509-A1 | TCR AND APPLICATION THEREOF | 深圳普瑞金生物药业有限公司 | 2022-08-18 | — | — | WO | disclosed |
| CN-114867819-A | Carbon quantum dots and uses thereof | 北京碳纳医疗科技有限公司 | 2022-08-05 | — | — | CN | disclosed |
| CN-114599382-A | Agonists of Tacr2 | 哥本哈根大学 | 2022-06-07 | — | — | CN | disclosed |
| EP-3997104-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B Pharmaceuticals GmbH (DE) | 2022-05-18 | — | — | EP | disclosed |
| WO-2021087645-A9 | USE OF CARBON QUANTUM DOTS FOR DETECTING OR TREATING CNS CANCER OR TUMOR | BEIJING NORMAL UNIVERSITY (CN) | 2022-05-12 | — | — | WO | disclosed |
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2022-05-05 | — | — | US | disclosed |
| US-20220087930-A1 | SARS-CoV-2 Subunit Vaccine and Microneedle Array Delivery System | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2022-03-24 | — | — | US | disclosed |
| WO-2022038131-A1 | METHOD FOR THE PREDICTION OF PROGRESSION OR PROGNOSIS OF THE RESPONSE OF A SUBJECT SUFFERING FROM ACUTE ORGAN DAMAGE | Plus Vitech, S.L. (ES) | 2022-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | OPRK1 2530/4885OPRM1 1737/4885OPRD1 2716/4885 |
| US-20260049331-A1 | Sense-and-Response of Proteins, Peptides, and Small Molecules Using Ligand-Induced Dimerization Activating RNA Editing (LIDAR) | ADAR, ZFR, SLIRP | OPRK1 2852/4885OPRM1 1894/4885OPRD1 2320/4885 |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | OPRK1 2530/4885OPRM1 1737/4885OPRD1 2716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.